Print

AVEG 029

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (VCP205) and HIV-1 SF-2 RGP-120 Administered in an Accelerated Schedule

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) July 31, 1996
rgp120/HIV-1 SF-2,ALVAC-HIV MN120TMG strain (vCP205) Canarypox Env gp120, TM gp41, gag, protease B MN/LAI; Protein Env gp120 B SF-2
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
rgp120/HIV-1 SF-2 Protein
USA 35
NCT00001076
http://www.clinicaltrials.gov/ct2/show/NCT00001076